Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies

Leukemia

Volumn 15, Issue 1, 2001, Pages 1-9

  Senderowicz, A M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Cell cycle; Cyclin D1; Cyclin dependent kinases; Flavopiridol; Protein kinases; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; FLAVOPIRIDOL; GEMCITABINE; OROSOMUCOID; PACLITAXEL; PLASMA PROTEIN; PROTEIN KINASE C INHIBITOR; RETINOBLASTOMA PROTEIN; STAUROSPORINE;

ACUTE LEUKEMIA; ANAPLASTIC CARCINOMA; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME INHIBITION; GENOTOXICITY; HEADACHE; HEMATOLOGIC DISEASE; HEMATOPOIETIC SYSTEM; HUMAN; HYPERGLYCEMIA; HYPOTENSION; HYPOXEMIA; IN VITRO STUDY; INFLAMMATION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEIOMYOSARCOMA; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MELANOMA; MITOSIS INHIBITION; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN PHOSPHORYLATION; STOMACH CARCINOMA; TRANSCRIPTION REGULATION;

EID: 0035141075     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401994     Document Type: Article

References (100)

1. Cancer cell cycles
2. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition
3. The regulation of E2F by pRB-family proteins
4. The role of RB in cell cycle control
5. The retinoblastoma protein and cell cycle control
6. Cyclin-dependent kinases: Engines, clocks, and microprocessors
7. Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II
8. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA
9. PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro
10. Cyclins, cyclin-dependent kinases and cdk inhibitors: Implications in cell cycle control and cancer
11. Identification of multiple cyclin subunits of human P-TEFb
12. CDK inhibitors: Positive and negative regulators of G1-phase progression
13. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)
14. Cyclins and cyclin-dependent kinases: Theme and variations
15. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma
16. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity
17. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation
18. Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma
19. Altered expression of the retinoblastoma tumor-suppressor gene in leukemic cell lines inhibits induction of differentiation but not G1-accumulation
20. Human T-cell leukemia virus type 1 Tax and cell cycle progression: Role of cyclin D-cdk and p110Rb
21. Mining the human proteome: Experience with the human lymphoid protein database
22. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer
23. Preclinical and clinical development of cyclin-dependent kinase modulators
24. Inhibition of CDKs as a therapeutic modality
25. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
26. Chemical inhibitors of cyclin-dependent kinases
27. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
28. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine
29. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
30. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
31. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275
32. Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural analogs
33. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity
34. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
35. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck
36. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers
37. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
38. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
39. Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells
40. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors
41. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes
42. Induction of differentiation accompanies inhibition of cdk2 in a non-small cell lung cancer cell line
43. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
44. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells
45. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
46. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
47. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human and leukemia xenografts
48. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
49. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
50. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
51. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate anti-apoptosis proteins in B-cell chronic lymphocytic leukemia
52. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519)
53. Flavopiridol-induced apoptosis is associated with a decrease in Cyclin D1 in mantle lymphoma cell lines
54. Clinical trials referral resource. Clinical trials of flavopiridol
55. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
56. Flavopiridol-induced apoptosis is associated with p38 and MEK activation and is prevented by caspase and MAPK inhibitors
57. Bcl-2 independence of flavopiridol-induced apoptosis: Mitochondrial depolarization in the absence of cytochrome c release
58. Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy
59. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
60. Phase I clinical and pharmacokinetic trial of flavopiridol
61. A Phase I trial of 1 hour infusion of flavopiridol (Fla), a novel cyclin-dependent kinase inhibitor, in patients with advanced neoplasms
62. Phase I trial of sequential paclitaxel and the cyclin-dependent kinase inhibitor flavopiridol
63. The cyclin-dependent kinase inhibitor flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer
64. A phase II trial of flavopiridol in patients with stage IV non-small cell lung cancer
65. Phase II trial of flavopiridol in metastatic colorectal cancer: Preliminary results
66. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago phase II Consortium study
67. Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors
68. UCN-01, a selective inhibitor of protein kinase C from Streptomyces
69. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities
70. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue
71. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells
72. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2
73. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models
74. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells
75. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells
76. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole
77. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin- dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line
78. Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines
79. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
80. Cell cycle checkpoints: Preventing an identity crisis
81. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25
82. UCN-01 abrogates G2 arrest through a cdc2-dependent pathway that involves inactivation of the Wee1Hu kinase
83. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine
84. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
85. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1
86. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
87. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells
88. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C
89. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor
90. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner
91. UCN-01 in ovary cancer cells: Effective as a single agent and in combination with cis-diamminedichloroplatinum(II) independent of p53 status
92. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor
93. The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma
94. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms
95. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
96. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein
97. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms
98. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: Presentation of a novel therapeutic paradigm
99. Phase I study of UCN-01 by 3-hour infusion
100. A phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor